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Abstract Sanglifehrin A (SFA) is a recently discovered immu-
nosuppressant drug that shares its intracellular target with the
major immunosuppressant drug cyclosporin A (CsA). Both bind
to and inhibit the cyclophilins, a diverse family of proteins found
throughout nature that share a conserved catalytic domain.
Although they share this common protein target, the mechanism
of action of the cyclophilin^SFA complex has been reported as
distinct from that of the well-studied cyclophilin^CsA complex.
The X-ray structure of a macrolide analogue of SFA’s cyclic
region complexed with cyclophilin A has recently been resolved,
but this left the placement of the linear region of SFA unre-
solved. Using ¢ve cyclophilins from the ¢ssion yeast Schizosac-
charomyces pombe, and a mutant of one of these proteins,
SpCyp3-F128W, we have shown that the sensitivity of cyclo-
philins to SFA can be correlated to the same speci¢c tryptophan
residue that has previously been identi¢ed to correlate to CsA
sensitivity, and that the tail of SFA may be responsible for
mediating this sensitivity.
- 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Cyclosporin A (CsA) is an important immunosuppressive
drug whose activity requires an interaction with a cyclophilin
[1]. Immunosuppression is caused by a cyclophilin^CsA com-
plex inhibiting the Ca2þ-dependent protein phosphatase calci-
neurin [1^3]. Proliferation of activated T-cells is dependent
upon the expression of the cytokine interleukin-2 [4,5]. Inter-
leukin-2 transcription is activated by the transcription factor
nuclear factor of activated T-cell, whose formation is due to
the localisation of the cytoplasmic component to the nucleus
through a calcineurin-initiated pathway. Blocking this path-
way leads to the inhibition of T-cell proliferation and there-
fore immunosuppression.
Sanglifehrin A (SFA) is a new immunosuppressant drug.
Shown to interact with human cyclophilin A [6] and more
recently mitochondrial cyclophilin D [7], it has a novel mech-
anism of immunosuppression that is distinct from CsA. SFA
blocks cell cycle progression from G1 through the nuclear
factor (NF)-UB-dependent activation of p53 [8,9], but inde-
pendent of the calcineurin-dependent deactivation of the
NF-UB inhibitor IUB/MAD3 [10]. Although the mechanism
is not yet fully understood, the cyclophilin^SFA complex
again binds to an intracellular protein that leads to the over-
production of p53.
In early 2002 the genome of the ¢ssion yeast Schizosacchar-
omyces pombe was completed by the sequencing consortium
led by the Sanger Centre [11] and we have previously reported
the identi¢cation of nine cyclophilins, of varying complexity,
that are encoded in the S. pombe genome [12]. We report here
the cloning and expression of ¢ve cyclophilins from S. pombe
(SpCyp1^5) with drug inhibition assays and tryptophan £uo-
rescence titrations showing that the sensitivity of the cyclo-
philins to the immunosuppressant drugs CsA and SFA can be
correlated to the same speci¢c tryptophan residue.
2. Materials and methods
2.1. Cloning, expression and puri¢cation of SpCyp1^5
SpCyp1^5 were cloned, expressed and puri¢ed as previously de-
scribed for SpCyp3 [12]. SpCyp2 and SpCyp5 were cloned from ge-
nomic DNA as they contain no introns, with SpCyp1 and SpCyp4
cloned from cDNA as they possess ¢ve introns and one intron respec-
tively [12]. SpCyp1 was polymerase chain reaction (PCR) ampli¢ed
from 2 Wl of cDNA produced by reverse transcription (RT)-PCR
using the enhanced avian RT-PCR kit (Sigma, Poole, UK) from
RNA puri¢ed from S. pombe cells using the RNeasy midi kit (Qiagen,
Hilden, Germany). SpCyp4 was cloned without its N-terminal signal
peptide as it proved insoluble when this was present, which mirrors
what was seen by Price et al. during their expression of its human
orthologue cyclophilin B [13]. All cyclophilins were expressed from the
pET21a expression system (Novagen, WI, USA), which gave them an
in-frame C-terminal (His)6 fusion tag, using the conditions previously
described by us [12] except for SpCyp1 which proved insoluble using
these conditions and was subsequently expressed at room temperature
and induced with 0.5 WM isopropyl thiogalactose (IPTG). Puri¢cation
was then achieved using the TALON Cell-Thru IMAC resin from BD
Biosciences (Oxford, UK) as per the manufacturers’ instructions.
2.2. PCR mutagenesis of SpCyp3
Two overlapping 30-mer primers were designed so that the phenyl-
alanine to tryptophan mutations (in bold) lay at their centre (5PC3P :
CGTTCCTTGCGATTGGTTGGACGGCAAAC, 3PC5P : GTTTG-
CCGTCCAACCAATCGCAAGGAACG). 50 Wl reactions were pre-
pared containing 0.5 Wl of a Qiagen miniprep (Hilden, Germany) of
the pET21a construct of the native gene, 2.5 pM of each primer, 2 Wl
of a 10 mM deoxyribonucleoside triphosphate (dNTP) mix (Invitro-
gen, The Netherlands), 1 Wl of Pfu DNA polymerase (Stratagene, UK)
and 5 Wl of 10U Pfu bu¡er. PCR was carried out in a Perkin-Elmer
GeneAmp PCR system 2400 thermocycler and cycled as follows: 94‡C
for 5 min (initial denaturing step), followed by 20 cycles of 94‡C for
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1 min (denaturing), 55‡C for 1 min (annealing) and 68‡C for 13 min
(extension). A ¢nal 68‡C for 7 min incubation was included before
placing the reactions at 4‡C. 1 Wl of the restriction endonuclease DpnI
(Promega, Southampton, UK) was added to remove template plasmid
DNA in a 1 h incubation at 37‡C followed by a 15 min incubation at
65‡C to inactivate the enzyme. 10 Wl of the reaction was then trans-
formed into chemically competent TOP-10 Escherichia coli cells and
plated onto Luria^Bertani (LB) plates containing 50 Wg/ml ampicillin
and grown overnight at 37‡C. Colonies were selected at random,
cultured in 10 ml LB media containing 50 Wg/ml ampicillin, Qiagen
miniprep (Hilden, Germany) and sent for sequencing to Oswel Re-
search Products (Southampton, UK) to con¢rm their identity prior to
expression as previously described [12].
2.3. Peptidyl-prolyl cis/trans isomerase (PPIase) assays and drug
inhibition
The SpCyp1^5 all showed strong PPIase activity with the synthetic
Ala-Pro peptide (N-succinyl-Ala-Ala-Pro-Phe-p-nitroanalide (succ-
AAPA-pNA); Sigma, Poole, UK) as a substrate compared to other
peptides tested and thus all the prolyl isomerase activities of the re-
combinant (His)6 fusion tagged cyclophilins were analysed with this
substrate using a previously published method [14] based on the orig-
inal method by Fischer et al. [15], except for SpCyp5 which used a
variation of this assay which replaces the protease chymotrypsin with
subtilisin [16] as it showed sensitivity to chymotrypsin (data not
shown). Reactions were performed in triplicate at 10‡C with measure-
ments taken at 390 nm using a Unicam UV3 spectrophotometer
(Cambridge, UK) for 150 s as previous investigations with other
PPIases (data not shown) had shown no e¡ect on subsequent calcu-
lations when reactions were monitored for longer. CsA (Sandoz Phar-
maceuticals, Basel, Switzerland) was used at concentrations of 1 nM^
10 WM and SFA (kind gift of Dr. Richard Sedrani, Novartis Pharma
AG, Switzerland) was used at concentrations of 1 pM^1 WM. Protein
stock concentrations were calculated using the Bradford assay (Bio-
Rad, Hercules, CA, USA) which was used in calculating the assay
concentration of protein. kcat/Km values were calculated as previously
described [17] and Ki values were calculated as previously described
[18] using the GraFit software package (Erithacus Software Ltd).
2.4. Fluorescence spectroscopy
The e¡ect of drug binding on the £uorescence of the tryptophan
residue present in the xLD motif of the active site of most of the
cyclophilins was assessed as previously described by Liu et al. [17]
using a Varian Cary Eclipse £uorescence spectrophotometer (Palo
Alto, CA, USA). CsA was titrated between 0.001 and 1000 nM and
SFA between 0.001 and 1000 pM as these seemed appropriate ranges
given the inhibition constants seen with the cyclophilins. Titrations
were performed with 50 nM cyclophilin, one sixth of that used by Liu
et al., as this was the lowest concentration of cyclophilin that gave a
reliably detectable and accurate signal on the equipment used. Each
data set was ¢tted in SigmaPlot version 8.03 (SPSS Inc.; Chicago, IL,
USA) using the equation previously published by Veitch et al. ([19];
eq. 1) in a plot of £uorescence change against drug concentration.
3. Results
We have previously reported the identi¢cation of the nine
SpCyps [12]. We have now cloned, expressed and puri¢ed ¢ve
of these, SpCyp1^5, that all have probable human ortho-
logues. All of the cyclophilins gave the expected PCR band
sizes from both genomic and complementary DNA con¢rmed
by sequencing after subcloning and prior to expression. Puri-
¢cation was con¢rmed using sodium dodecyl sulphate^poly-
acrylamide gel electrophoresis (SDS^PAGE) and Western
blotting using a (His)6 fusion tag antibody (P¢zer, Sandwich,
UK). The puri¢ed cyclophilin proteins can be seen in Fig. 1.
3.1. PPIase assays
Prolyl isomerase assays were carried out as described above
using the puri¢ed (His)6 fusion tagged proteins. X-ray crys-
tallography studies on orthologues of the SpCyps have shown
that the C-termini of the proteins are located on the opposite
side to the active site (SpCyp2^4; [20^22] respectively), or in
the case of SpCyp5 in the non-PPIase C-terminal domain [23].
Any small C-terminal fusion tag, such as the (His)6 tag used,
should therefore not a¡ect substrate or drug binding.
Fig. 1. 15% SDS^PAGE gel and alkaline phosphatase Western blot
of the puri¢ed SpCyps. SpCyp1 (lane 1), SpCyp2 (lane 2), SpCyp3
(lane 3), SpCyp3-F128W mutant (lane 4), SpCyp4 (lane 5) and
SpCyp5 (lane 6). SpCyp1, SpCyp2 and SpCyp4 ran at their pre-
dicted Mw of 17.4, 16.9 and 22.2 kDa respectively. SpCyp3 and its
F128W mutant ran larger than their predicted 18.9 kDa at about
21 kDa, which can be explained by their pI of 5.61. SpCyp5 ran
larger than the predicted 40.2 kDa, at about 50 kDa, which cannot
be explained by its pI of 8.05. Molecular weight marker sizes are
shown down the left hand side of the images in kDa.
Table 1
The catalytic e⁄ciencies (kcat/Km) and drug inhibition constants (Ki) of the puri¢ed SpCyps
xLD kcat/Km (WM31 s31) Ki CsA (nM) Ki SFA (pM)
SpCyp1 WLD 2.0 27S 8.2 3.5S 0.5
SpCyp2 WLD 11.0 26S 5.2 1.2S 0.5
SpCyp3 FLD 11.0 1800S 450 450S 140
SpCyp4 WLD 8.8 15S 3.5 1.7S 0.2
SpCyp5 HLD 4.1 420S 200 130S 51
SpCyp3-F128W WLD 11.0 14S 5.0 0.2S 0.1
kcat/Km given for the succ-AAPF-pNA tetrapeptide substrate (WM31 s31 ; 2 s.f.) and drug inhibition constants (2 s.f. S error) for both CsA
(nM) and SFA (pM). Errors stated were produced by the Gra¢t programme when calculating the constant and thus represent its con¢dence
level.
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Table 1 shows the catalytic e⁄ciencies (kcat/Km) of the cy-
clophilins with the succ-AAPF-pNA substrate and their inhi-
bition constants (Ki) with both CsA and SFA. An example
graph illustrating the e¡ect of the two inhibitory drugs on the
catalytic activity of SpCyp2, seen using the PPIase spectro-
photometric assay, and subsequently used in kcat/Km and Ki
calculations, can be found in Fig. 2.
The cyclophilins show a range of activities on the succ-
AAPA-pNA tetrapeptide substrate. SpCyp2 and SpCyp3
show the greatest activity with kcat/Km values of 11.3 and
11.2 WM31 s31 respectively. These are close to the values of
14.6 [14], 16 [13] and 17 [17] WM31 s31 reported for human
cyclophilin A in three separate studies and 11 WM31 s31 re-
ported for Zea mays cyclophilin A [24]. SpCyp4 showed an
activity of 8.79 WM31 s31, comparable to the activity reported
for human cyclophilin B [13] and Orpinomyces sp. cyclophilin
B [25], which showed 6.3 and 9.3 WM31 s31 respectively, but
only about a third of the 25 WM31 s31 reported for Z. mays
cyclophilin B [24]. SpCyp5 showed an activity of 0.27 WM31
s31 when using chymotrypsin in the assay, which is compara-
ble to the values reported for its Saccharomyces cerevisiae
orthologues Cpr6, which gave 0.48 [26] and 0.5 [27] WM31
s31 and Cpr7 with 0.08 WM31 s31 [26]. This activity increased
to 4.14 WM31 s31 when the assays were repeated with subti-
lisin after SpCyp5 was found to be sensitive to chymotrypsin
(data not shown), showing that the degradation did have an
e¡ect on the protein activity and may also explain the low
activities seen with its S. cerevisiae orthologues if they share
this sensitivity to chymotrypsin. The lowest activity was seen
with SpCyp1, which showed an activity of 1.98 WM31 s31.
This is 33 times that of the lowest currently reported activity,
which was that of Drosophila melanogaster Moca-CyP with a
rate of 0.06 WM31 s31 [28].
The inhibition constants (Ki) on CsA show that SpCyp1
and SpCyp2 have about the same sensitivity with Ki’s of
around 27 nM. These values are higher than the 2.6 nM
reported previously for human cyclophilin A [29] and the
6 nM reported with Z. mays cyclophilins A and B [24].
SpCyp4 is the most sensitive with a slightly lower Ki of 14.6
nM, but this is still higher than the lowest observed Ki’s which
were seen with Brugia malayi cyclophilins 1 and 2 of less than
0.5 nM [30]. SpCyp3 and SpCyp5 gave Ki’s of 1762 and 423
nM respectively, which are markedly higher than those of
SpCyp1, SpCyp2 and SpCyp4.
This reduction in drug sensitivity can be correlated, as pre-
viously reported [17,31], to a variation in the residue found in
the ‘x’ position of the xLD motif located in the active site of
the cyclophilins [12]. The presence of a tryptophan in this
position, as is found in SpCyp1, SpCyp2 and SpCyp4, confers
the greatest sensitivity whereas the presence of a phenylala-
nine, as is found in SpCyp3, confers the least sensitivity with
the presence of a histidine, as is found in SpCyp5, conferring a
sensitivity between that of tryptophan and phenylalanine.
This result shows the same pattern seen when Liu et al. com-
pared the presence of a tryptophan or phenylalanine in both
E. coli and human cyclophilin A [17] and Ho¡mann et al.
compared the presence of a tryptophan in place of the wild-
type histidine in human cyclophilin 40 [31].
The most striking feature of the inhibition constants seen
with SFA, besides its greater potency which has been previ-
ously reported [6], is that they follow the same pattern of drug
sensitivity than that is seen with CsA with regards to the xLD
isoforms. SpCyp2 and SpCyp4 show similar Ki values of
about 1.5 pM with SpCyp1 showing a slightly higher Ki of
3.53 pM. All possess a tryptophan in the xLD motif, with
conservation seen at all other positions that contact CsA ex-
cept for the two variations seen in SpCyp1 which appear not
to cause any major e¡ect. The presence of a phenylalanine in
the xLD motif (SpCyp3) again causes an order of magnitude
greater insensitivity to SFA in a ratio close to that seen with
CsA. The presence of a histidine (SpCyp5) again gives a Ki
that is in between those that possess a tryptophan or phenyl-
alanine. It is important to note, however, that although the
same pattern of sensitivity is seen with regards to the xLD
isoform, the cyclophilins possessing a tryptophan vary in sen-
sitivity di¡erently to that seen with CsA, inferring that some
di¡erent residues in the active site are also involved in con-
ferring SFA sensitivity, but their e¡ect is less pronounced.
3.2. Cyclophilin 3 mutagenesis
To con¢rm that the drug sensitivity pattern seen with SFA,
which appears to correlate to the speci¢c tryptophan residue
in the xLD motif, is in fact due to this residue, a mutant
SpCyp3 was constructed using PCR mutagenesis replacing
the wild-type phenylalanine with tryptophan to produce an
SpCyp3-F128W protein. After sequencing con¢rmed that the
engineered mutation was the only deviation from wild-type, it
was expressed as previously described for cyclophilin 3 [12]
and its puri¢cation con¢rmed using SDS^PAGE and Western
blotting using a (His)6 fusion tag antibody (P¢zer, Sandwich,
UK). The puri¢ed protein can be seen in lane 4 of Fig. 1.
Catalytic e⁄ciency and drug sensitivity assays were then car-
ried out and the results shown in Table 1.
The drug inhibition assays showed that the sensitivity of the
SpCyp3-F128W mutant to both CsA and SFA is an order of
magnitude greater than that of the wild-type protein to both
inhibitors whilst PPIase activity assays show that the protein’s
catalytic activity has not been signi¢cantly altered. The wild-
type protein sensitivity to CsA was 1762.64 nM compared to
the mutant sensitivity (13.45 nM) and the SFA sensitivities
were 451.64 pM compared to 0.23 pM respectively. Compar-
ing these to the sensitivities of the other proteins investigated
in this study, SpCyp3-F128W CsA sensitivity of 13.45 nM is
approximately the same as that of cyclophilin 4 which gave a
Fig. 2. E¡ect of cyclophilin inhibiting drugs on the activity of
SpCyp2. Plots of change in absorbance against assay time in the
presence and absence of the two inhibiting drugs, CsA and SFA,
obtained using the PPIase spectrophotometric assay.
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value of 14.56 nM, the lowest seen in the wild-type proteins,
and which also possesses a tryptophan at its ‘x’ position. Its
SFA sensitivity is the highest we have observed from these six
proteins, with a Ki value of 0.23 pM.
3.3. Comparison of CsA and SFA binding
Sedrani et al. recently published the X-ray structure of cy-
clophilin A complexed with a macrolide analogue of the cyclic
region of SFA [32] which binds in the active site cleft of the
cyclophilin, as does CsA [33]. Fig. 3 shows a molecular
graphics comparison of CsA and the SFA macrolide analogue
bound in the active site of cyclophilin A. The theoretical con-
tact points between the cyclophilin and the drug were calcu-
lated and are indicated by rings. It is interesting to see that
although they both bind into the active site, CsA has nine
contact points to SFA eight, which is surprising given its
greater a⁄nity for the cyclophilin. The active site appears to
have a slightly di¡erent conformation between the two bound
forms, which may account for the two drugs sharing only six
contact points, but more importantly the two interactions
CsA has with the tryptophan residue in the xLD motif
(Trp121) are not shared with the macrolide analogue of the
cyclic region of SFA. Why therefore does this residue corre-
late with the cyclophilins sensitivity to SFA? It could possibly
be due to conformational changes induced by the presence of
phenylalanine or histidine within the active site itself that lead
to its reduced a⁄nity. What is missing from this picture is the
location of the linear region of SFA that is attached to the
cyclic ring of the macrolide. From the position of the macro-
lide component residues in the structure, the linear ‘tail’ re-
gion will extend down from the active site taking it past the
tryptophan residue. This could therefore contact this residue
and lead to the observed e¡ect changing this residue has on
SFA sensitivity.
3.4. Tryptophan £uorescence titrations
To con¢rm that SFA does in fact bind near to, and poten-
tially contact, the tryptophan residue in the xLD motif by
virtue of its ‘tail’ region, £uorescence assays were performed
as previously reported by Liu et al. [17] in the analysis of CsA
binding to various cyclophilin mutants. The proximity of the
drug to the tryptophan residue causes an increase in its reso-
nance through changes in its local environment which lead to
an increase in its emission intensity when excited. By monitor-
ing the emissions in the presence of an increasing drug con-
centration allows us to see if the drug binds near the residue.
Fig. 4 shows the plots of the change in tryptophan £uores-
cence seen upon drug addition to SpCyp1^5 and the SpCyp3-
F128W mutant. It is evident that no change in £uorescence is
seen with SpCyp3 and SpCyp5 upon the addition of either
drug, which is as expected as they possess no tryptophan in
their xLD motif. However, with the addition of either CsA or
SFA, SpCyp1, SpCyp3-F128W and SpCyp4 show an increase
in £uorescence to a maximum that varies between the cyclo-
philins. This variation is due to the bound drug having di¡er-
ing e¡ects on tryptophan £uorescence when saturating the
di¡erent cyclophilins, which may be due to di¡erences in the
distance and geometry of the bound drug to the tryptophan or
Fig. 3. Molecular graphics comparison of the binding of CsA and
SFA. (A) shows CsA [33] and (B) shows macrolide 16 [32], an ana-
logue of SFA’s cyclic region that binds to the cyclophilin, bound to
the active site of human cyclophilin A. Images were produced using
Protein Explorer [34] with the contact surface between the protein
and ligand predicted and points of theoretical contact marked by
the rings.
Fig. 4. Fluorescence titration graphs of the puri¢ed SpCyps.
(A) shows the change in £uorescence upon the addition of CsA
over the range of 0^100 nM and (B) shows the change in £uores-
cence upon the addition of SFA over the range of either 0^100 pM
(upper) or 0^500 pM (lower).
FEBS 27864 19-11-03
T.J. Pemberton, J.E. Kay/FEBS Letters 555 (2003) 335^340338
in the level of solvation change around the tryptophan upon
drug binding.
These data con¢rm that some part of SFA does bind in
close proximity to the tryptophan residue in the xLD motif.
This is most likely the ‘tail’ region of the drug given the
position and orientation of the cyclic region in the active site.
4. Discussion
We have reported here the cloning, expression and catalytic
characterisation of four SpCyps, that all have identi¢ed or-
thologues in humans [12]. We had previously reported the
cloning and characterisation of SpCyp3 [12], which was also
investigated in this paper.
The SpCyps have shown comparable activity on the tetra-
peptide substrate succ-AAPF-pNA to those orthologues that
have previously been reported from other species. SpCyp2 and
SpCyp3 showed the greatest activity which was roughly ¢ve
times that of the lowest, SpCyp1.
CsA sensitivity assays showed SpCyp1, SpCyp2 and
SpCyp4 to have comparable Ki’s but SpCyp3 and SpCyp5
showed a lower sensitivity to the drug. This reduced sensitivity
can be correlated to a speci¢c tryptophan residue in the xLD
motif, as has been previously reported by Liu et al. using
mutagenesis experiments with human cyclophilin A [17] and
Ho¡mann et al. with human cyclophilin 40 [31]. The presence
of a phenylalanine conferred an order of magnitude lower
sensitivity than tryptophan, with a histidine conferring an
intermediate sensitivity.
Inhibition assays with the novel cyclophilin-targeting immu-
nosuppressant drug SFA con¢rmed that the drug is more
potent than CsA at inhibiting the SpCyps, as previously re-
ported for human cyclophilin A [6]. The results also showed
that the sensitivity of the cyclophilins to SFA can be corre-
lated to the same speci¢c tryptophan residue as CsA.
Construction of a cyclophilin 3-F128W mutant con¢rmed
directly that the sensitivity of cyclophilin 3 to both CsA and
SFA can be correlated to the ‘x’ residue in the xLD motif, and
given the results of the wild-type proteins, this can be inferred
to be true for all cyclophilins. This observation implies that
part of the SFA molecule binds in close proximity to the ‘x’
residue. The comparable catalytic activity of cyclophilin 3 and
the F128W mutant agreed with Liu et al.’s observation that
variations in this position do not a¡ect the prolyl isomerase
activity of the cyclophilin [17].
Molecular graphics analysis of CsA bound to cyclophilin A
[33] compared to the recent structure of a macrolide analogue
of the cyclic region of SFA bound to cyclophilin A [32]
showed that the cyclic region does not bind in the proximity
of the tryptophan residue. However, the binding of SFA in
close proximity to the tryptophan residue in the xLD motif
has been con¢rmed by tryptophan £uorescence titrations that
show an increase in £uorescence in the presence of the drug.
This leads us to the conclusion that it is the linear ‘tail’ region
of SFA that binds in close proximity to the variable ‘x’ residue
in the xLD motif and this therefore leads to the observed
variability in sensitivity of the cyclophilins to SFA.
SpCyp1 and SpCyp2 show similar maxima in the £uores-
cence titrations with CsA and SFA, but SpCyp3-F128W and
SpCyp4 have lower maxima with SFA than with CsA, sug-
gesting that SFA binds further away from, or in a di¡erent
geometry in relation to, the tryptophan than CsA in these two
cases. The SpCyp3-F128W mutant also showed a signi¢cantly
lower a⁄nity for SFA than CsA in the £uorescence titrations
as a greater concentration of SFA is required for it to reach
its £uorescence maximum. This reduced a⁄nity is not re-
£ected in the inhibition constant, inferring that this re£ects
a structural feature that signi¢cantly a¡ects SFA, but not
CsA, binding in the vicinity of the tryptophan and that this
doesn’t a¡ect its overall binding. We would conclude that this
feature a¡ects the positioning of the ‘tail’ region about the
tryptophan, which therefore appears to have little e¡ect on
the drugs a⁄nity, rather than in the binding of the cyclic
region. This is supported by Sedrani et al., who reported
that the macrolide analogue of SFA’s cyclic region bound
to human cyclophilin A with an almost identical a⁄nity to
that of the complete SFA molecule [32].
The reasons why reduced drug sensitivity is seen with those
cyclophilins possessing a phenylalanine or histidine in place of
this tryptophan cannot be explained by these £uorescence
data. As the positioning of the ‘tail’ around the tryptophan
appears to have little e¡ect on SFA’s a⁄nity for the cyclo-
philin, its repositioning in the presence of the other two res-
idues is unlikely to cause the signi¢cant change in a⁄nity we
have observed. This therefore makes changes in the structure
of the active site that occur in the presence of the other two
residues the most likely cause.
Further work is therefore needed to identify all the factors
that a¡ect SFA binding, with the SpCyps representing a good
model group for this to be performed with. The e¡ect of the
macrolide analogue of SFA’s cyclic region on the catalytic
activity of these cyclophilins will show whether or not it is
structural changes within the active site that lead to the re-
duced a⁄nity in the phenylalanine and histidine containing
cyclophilins. Should its inhibition constants be those seen
with the complete SFA molecule then this would infer that
it is, whereas inhibition constants that show an a⁄nity about
those of the tryptophan containing cyclophilins would infer
that this change in a⁄nity is due to an interaction of the ‘tail’
region. Structural data on a cyclophilin with the complete
SFA molecule will be of great use as it will allow us to better
understand the positioning of the ‘tail’ region in relation to
the tryptophan residue, and if also possible with a cyclophilin
possessing a phenylalanine or histidine, a comparison might
allow us to identify the factors that lead to reduced drug
a⁄nity.
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